How Is Muscular Fibroma Treated?

Muscle fibromas—also known as intramuscular fibromas—are rare, benign soft-tissue tumors that arise within skeletal muscle. They are composed of mature fibroblasts and collagen bundles, typically lacking significant cellular atypia or mitotic activity. Because they are non-metastatic and grow slowly, management is primarily conservative.

Diagnosis requires a combination of clinical evaluation, cross-sectional imaging (such as MRI), and histopathologic confirmation via biopsy or excisional specimen. MRI usually reveals a well-circumscribed, T1- and T2-hypointense mass embedded within muscle, often with low signal intensity on all sequences due to dense collagen content. Differential diagnoses include desmoid-type fibromatosis, solitary fibrous tumor, and low-grade fibromyxoid sarcoma—making expert pathological review essential.

Asymptomatic lesions discovered incidentally may be managed with active surveillance: serial clinical assessments and periodic MRI monitoring every 6–12 months to evaluate for growth or symptom development. Intervention is indicated only when the lesion causes pain, functional impairment, progressive enlargement, or diagnostic uncertainty.

Surgical excision remains the definitive treatment for symptomatic or enlarging muscle fibromas. Wide local excision is generally unnecessary; marginal resection with clear margins is sufficient given the tumor’s benign biology and extremely low recurrence risk. Incomplete resection does not predispose to malignant transformation, though residual tissue may rarely prompt repeat intervention if symptoms recur.

Adjuvant therapies—including radiation and systemic agents—have no established role in the management of muscle fibroma, as these tumors are neither radiosensitive nor responsive to chemotherapy or targeted agents. Patients should be counseled that long-term prognosis is excellent, with no impact on life expectancy or systemic health.